Santen Corporate (en)

2026 Press Release

Press Release

Santen Publishes its Annual Integrated Report “Santen Report 2026”
Santen Announces the Transfer of Advanced Vision Science, Inc.
Santen New Drug Application Filing Accepted for Review in China for STN1012700 (Atropine Sulfate Ophthalmic Solution 0.025%), an Ophthalmic Solution to Slow the Progression of Myopia
Santen Launches Rhopressa® Ophthalmic Solution 0.02% in Japan, a Treatment for Glaucoma and Ocular Hypertension
Santen Joins Inaugural Global Summit for Eye Health as High-Impact Partner
Santen and KYORIN announce joint marketing agreement in Japan for allergic conjunctivitis treatment Alesion® Eyelid Cream 0.5%
Santen Obtains Marketing Approval in the Philippines for STN1012700 (Ryjusea 0.25mg/mL Ophthalmic Solution), an Ophthalmic Solution to Slow the Progression of Myopia — First Approval in Santen’s Asia Business Region
Santen Obtains Manufacturing and Marketing Approval in Japan for Rhopressa® Ophthalmic Solution 0.02%, a Treatment for Glaucoma and Ocular Hypertension
Santen China Signs Exclusive Distribution and Promotion Agreement for Five Marketed Glaucoma Eyedrops Products in the Chinese Mainland
Santen to Launch UPNEEQ® Mini Ophthalmic Solution 0.1%, a Treatment for Acquired Blepharoptosis
Notice of Board of Director and Corporate Auditor Nominations
Launch of Aflibercept kit for IVT inj. 40 mg/mL Bayer